Willand Pharma Limited 11037039 false 2024-04-01 2025-03-31 2025-03-31 The principal activity of the company is that of a holding company. Digita Accounts Production Advanced 6.30.9574.0 false true 11037039 2024-04-01 2025-03-31 11037039 2025-03-31 11037039 bus:OrdinaryShareClass1 2025-03-31 11037039 bus:OrdinaryShareClass2 2025-03-31 11037039 bus:OrdinaryShareClass3 2025-03-31 11037039 core:ShareCapital 2025-03-31 11037039 core:CurrentFinancialInstruments 2025-03-31 11037039 core:CurrentFinancialInstruments core:WithinOneYear 2025-03-31 11037039 core:CostValuation 2025-03-31 11037039 bus:SmallEntities 2024-04-01 2025-03-31 11037039 bus:AuditExemptWithAccountantsReport 2024-04-01 2025-03-31 11037039 bus:FilletedAccounts 2024-04-01 2025-03-31 11037039 bus:SmallCompaniesRegimeForAccounts 2024-04-01 2025-03-31 11037039 bus:RegisteredOffice 2024-04-01 2025-03-31 11037039 bus:Director1 2024-04-01 2025-03-31 11037039 bus:Director2 2024-04-01 2025-03-31 11037039 bus:OrdinaryShareClass1 2024-04-01 2025-03-31 11037039 bus:OrdinaryShareClass2 2024-04-01 2025-03-31 11037039 bus:OrdinaryShareClass3 2024-04-01 2025-03-31 11037039 bus:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 11037039 bus:Agent1 2024-04-01 2025-03-31 11037039 core:AllSubsidiaries 2024-04-01 2025-03-31 11037039 core:KeyManagementPersonnel 2024-04-01 2025-03-31 11037039 core:KeyManagementPersonnelCloseFamilyMembersEntitiesUnderKeyManagementPersonnelsControl 2024-04-01 2025-03-31 11037039 countries:EnglandWales 2024-04-01 2025-03-31 11037039 core:CostValuation 2024-03-31 11037039 2023-04-01 2024-03-31 11037039 2024-03-31 11037039 bus:OrdinaryShareClass1 2024-03-31 11037039 bus:OrdinaryShareClass2 2024-03-31 11037039 bus:OrdinaryShareClass3 2024-03-31 11037039 core:CurrentFinancialInstruments 2024-03-31 11037039 core:CurrentFinancialInstruments core:WithinOneYear 2024-03-31 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 11037039

Prepared for the registrar
Willand Pharma Limited
Annual Report and Unaudited Financial Statements
for the Year Ended 31 March 2025

Willand Pharma Limited

Contents

Company Information | 1
Balance Sheet | 2
Notes to the Unaudited Financial Statements | 3 to 6

Willand Pharma Limited

Company Information

Directors | Cristina Alonso-Sanchez Ivan Ferri-Jimenez

Registered office | Willand Pharmacy Linacre House Gables Road Willand Cullompton Devon EX15 2PL

Accountants | Hazlewoods LLP Staverton Court Staverton Cheltenham GL51 0UX

Willand Pharma Limited

(Registration number: 11037039)
Balance Sheet as at 31 March 2025

| Note | 2025 £ | 2024 £
Fixed assets |  |  |
Investments | 4 | 868,515 | 868,515
Current assets |  |  |
Cash at bank and in hand |  | 408 | 302
Creditors: Amounts falling due within one year | 5 | (612,444) | (562,830)
Net current liabilities |  | (612,036) | (562,528)
Net assets |  | 256,479 | 305,987
Capital and reserves |  |  |
Called up share capital | 7 | 100 | 100
Retained earnings |  | 256,379 | 305,887
Shareholders' funds |  | 256,479 | 305,987

For the financial year ending 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

• | The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and
• | The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the Board on 16 October 2025 and signed on its behalf by:

Ivan Ferri-Jimenez
Director

Willand Pharma Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

| 1 | General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
Willand Pharmacy
Linacre House Gables Road
Willand
Cullompton
Devon
EX15 2PL

| 2 | Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except for, where disclosed in these accounting policies, certain items that are shown at fair value.

The presentational currency of the financial statements is Pounds Sterling, being the functional currency of the primary economic environment in which the company operates. Monetary amounts in these financial statements are rounded to the nearest Pound.

Going concern

Critical accounting judgements and key sources of estimation uncertainty
In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.
The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

Judgements

No significant judgements have been made by management in preparing these financial statements.

Key sources of estimation uncertainty

No key sources of estimation uncertainty have been identified by management in preparing these financial statements other than those detailed in these accounting policies.

Business combinations

Business combinations are accounted for using the purchase method. The consideration for each acquisition is measured at the aggregate of the fair values at acquisition date of assets given, liabilities incurred or assumed, and equity instruments issued by the group in exchange for control of the acquired, plus any costs directly attributable to the business combination. When a business combination agreement provides for an adjustment to the cost of the combination contingent on future events, the group includes the estimated amount of that adjustment in the cost of the combination at the acquisition date if the adjustment is probable and can be measured reliably.

Willand Pharma Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

Investments

Investments in equity shares which are publicly traded or where the fair value can be measured reliably are initially measured at fair value, with changes in fair value recognised in profit or loss. Investments in equity shares which are not publicly traded and where fair value cannot be measured reliably are measured at cost less impairment.
Interest income on debt securities, where applicable, is recognised in income using the effective interest method. Dividends on equity securities are recognised in income when receivable.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.
Trade creditors are recognised initially at the transaction price and all are repayable within one year and hence are included at the undiscounted amount of cash expected to be paid.

Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the profit and loss account over the period of the relevant borrowing.
Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.
Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

Leases

Leases in which substantially all the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases are charged to profit or loss on a straight-line basis over the period of the lease.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

Willand Pharma Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

Financial instruments

Classification
Financial instruments are classified and accounted for according to the substance of the contractual arrangement, as financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities. Where shares are issued, any component that creates a financial liability of the company is presented as a liability on the balance sheet. The corresponding dividends relating to the liability component are charged as interest expenses in the profit and loss account.
Recognition and measurement
All financial assets and liabilities are initially measured at transaction price (including transaction costs), except for those financial assets classified as at fair value through profit or loss, which are initially measured at fair value (which is normally the transaction price excluding transaction costs), unless the arrangement constitutes a financing transaction. If an arrangement constitutes a financing transaction, the financial asset or financial liability is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.
Impairment
Assets, other than those measured at fair value, are assessed for indicators of impairment at each balance sheet date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss as described below.
A non financial asset is impaired where there is objective evidence that, as a result of one or more events that occurred after initial recognition, the estimated recoverable value of the asset has been reduced. The recoverable amount of an asset is the higher of its fair value less costs to sell and its value in use.

| 3 | Staff numbers

The average number of persons employed by the company (including directors) during the year, was as follows:

| 2025 No. | 2024 No.
Average number of employees | 2 | 2

| 4 | Investments

| 2025 £ | 2024 £
Investments in subsidiaries | 868,515 | 868,515

Subsidiaries | £
Cost
At 1 April 2024 | 868,515
At 31 March 2025 | 868,515
Carrying amount
At 31 March 2025 | 868,515
At 31 March 2024 | 868,515

Willand Pharma Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

| 5 | Creditors

| Note | 2025 £ | 2024 £
Due within one year |  |  |
Loans and borrowings | 6 | 291,548 | 245,058
Amounts due to related parties |  | 320,228 | 317,131
Accrued expenses |  | 668 | 641
|  | 612,444 | 562,830

| 6 | Loans and borrowings

Current loans and borrowings

| 2025 £ | 2024 £
Other borrowings | 291,548 | 245,058

| 7 | Share capital

Allotted, called up and fully paid shares

| 2025 | 2024
| No. | £ | No. | £
Ordinary A shares of £1 each | 33 | 33 | 33 | 33
Ordinary B shares of £1 each | 33 | 33 | 33 | 33
Ordinary C shares of £1 each | 34 | 34 | 34 | 34
| 100 | 100 | 100 | 100

The different classes of share referred to above carry separate rights to dividends but, in all other significant respects, rank pari passu.

| 8 | Related party transactions

Key management personnel

Summary of transactions with key management

Key management personnel are considered to be the directors of the company.

Summary of transactions with subsidiaries

AK Pharma Limited As at 31 March 2025 the company owed AK Pharma Limited £320,228 (2024 - £317,131). No interest is charged on the loan and there are no fixed repayment terms.